PATENT LICENSE AGREEMENT – EXCLUSIVEPublic Health Service • October 15th, 2021 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
BIOLOGICAL MATERIALS LICENSE AGREEMENT INTERNAL USE ONLYPublic Health Service • October 15th, 2021 • District of Columbia
COMMERCIAL EVALUATION - BIOLOGICAL MATERIALS LICENSE AGREEMENTPublic Health Service • October 15th, 2021
NON-EXCLUSIVE PATENT LICENSE AGREEMENT FOR INTERNAL RESEARCH USEPublic Health Service • September 29th, 2021 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), Appendix D (Shipping Information) and Appendix E (Royalty Payment Options).
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT-Public Health Service • February 21st, 2018 • District of Columbia
This agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
This Agreement is based on the model Cost Sharing Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and...Public Health Service • January 31st, 2022 • District of Columbia
COMMERCIAL EVALUATION LICENSE AGREEMENTPublic Health Service • October 15th, 2021
INTERINSTITUTIONAL AGREEMENT INSTITUTION-LEADPublic Health Service • January 31st, 2022 • District of Columbia
BIOLOGICAL MATERIALS LICENSE AGREEMENTPublic Health Service • October 15th, 2021
PUBLIC HEALTH SERVICEPublic Health Service • May 10th, 2022
This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and...Public Health Service • October 15th, 2021
This is the amendment (“ Amendment”) of the agreement by and between the IC and Licensee having an effective date of and having IC Reference Number L-XXX-200X/X (“Agreement”). This Amendment, having IC Reference Number L-XXX-200X/X includes, in addition to the amendments made below,
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVEPublic Health Service • September 10th, 2021
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
INTERINSTITUTIONAL AGREEMENT IC-LEADPublic Health Service • January 31st, 2022 • District of Columbia
This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease...Public Health Service • May 10th, 2022 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
Exhibit 10.3 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT This Cooperative Research and Development Agreement, hereinafter referred to as the "CRADA," consists of this Cover Page, an attached Agreement, and various Appendices...Public Health Service • December 11th, 2001 • Protarga Inc • District of Columbia
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTPublic Health Service • March 24th, 2016 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHPublic Health Service • November 29th, 2011 • Genesis Biopharma, Inc • Arrangement of transportation of freight & cargo • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease...Public Health Service • September 30th, 2021
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTPublic Health Service • October 5th, 2007 • BG Medicine, Inc. • Services-medical laboratories • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTPublic Health Service • December 10th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT This Cooperative Research and Development Agreement, hereinafter referred to as the "CRADA," consists of this Cover Page, an attached Agreement, and various Appendices referenced in...Public Health Service • August 13th, 1999 • Neopharm Inc • Services-commercial physical & biological research • District of Columbia
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTPublic Health Service • January 23rd, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • District of Columbia
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGEPublic Health Service • March 31st, 2009 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
COMMERCIAL EVALUATION - BIOLOGICAL MATERIALS LICENSE AGREEMENTPublic Health Service • February 10th, 2016
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE EVALUATION OPTION LICENSE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by...Public Health Service • November 7th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Royalty Payment Option), and Appendix G (Shipping Information).
PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE This Agreement is based on the model Patent License Non-Exclusive Sublicensable Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of...Public Health Service • April 1st, 2019 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR NCI DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD) EXTRAMURAL PHS CLINICAL RESEARCHPublic Health Service • March 13th, 2018 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted on December 8, 2010 by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
COMMERCIAL EVALUATION LICENSE AGREEMENTPublic Health Service • December 6th, 2004 • Us Biodefense Inc • Services-business services, nec • District of Columbia
This Agreement is entered into between the National Institutes of Health ("NIH"), the Centers for Disease Control and Prevention ("CDC"), or the Food and Drug Administration ("FDA"), hereinafter singly or collectively referred to as "PHS", agencies of the United States Public Health Service within the Department of Health and Human Services ("DHHS") through the Office of Technology Transfer, National Institutes of Health, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A. and U.S. Biodefense, Inc. ("Licensee"), a corporation of Utah, having an office at 13674 East Valley Blvd., City of Industry, CA 91746.
PUBLIC HEALTH SERVICE START-UP EXCLUSIVE EVALUATION OPTION LICENSE AGREEMENTPublic Health Service • October 30th, 2018 • District of Columbia
By assignment of rights from IC employees and other inventors, HHS, on behalf of the Government, owns certain intellectual property rights in the United States or foreign patent applications and/or patents of the Licensed Patent Rights.
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR NCI DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD) EXTRAMURAL PHS CLINICAL AND NON-CLINICAL RESEARCHPublic Health Service • April 1st, 2022 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted on December 8, 2010 by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Amendment #1 Cooperative Research and Development Agreement # 02734 Development and Evaluation of the NCI Proprietary Adoptive Cell Transfer Immunotherapy Using Tumor Infiltrating Lymphocytes in Patients with Metastatic Melanoma, Utilizing Genesis...Public Health Service • January 27th, 2015 • Lion Biotechnologies, Inc. • Biological products, (no disgnostic substances)
The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA remain in full force and effect. Two originals of this amendment are provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.
Cooperative Research and Development Agreement (CRADA 02177) Cooperative and Research Development Agreement for the Development of Introgen Proprietary Vectors and Recombinants for the Treatment of Cancer Steven A. Rosenberg, M.D., Ph.D. Surgery...Public Health Service • May 4th, 2007 • Introgen Therapeutics Inc • Pharmaceutical preparations • District of Columbia
or administrative body of competent jurisdiction, or federal law or regulation. Each Party agrees to use reasonable efforts to maintain the confidentiality of Confidential Information, which will in no instance be less effort than the Party uses to protect its own Confidential Information. Each Party agrees that a Party receiving Confidential Information will not be liable for the disclosure of that portion of the Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld, provided the disclosing Party has been given a reasonable opportunity to seek a court order to enjoin disclosure.
ContractPublic Health Service • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances)
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
BIOLOGICAL MATERIALS LICENSE AGREEMENT INTERNAL USE ONLY This Agreement is based on the model Biological Materials Internal Use Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the...Public Health Service • October 14th, 2016 • District of Columbia
The Licensee desires to obtain a license from the IC to use the Materials provided under this Agreement in its commercial research or product development and marketing activities. The Licensee represents that it has the facilities, personnel, and expertise to use the Materials or the Licensed Products for commercial purposes and agrees to expend reasonable efforts and resources to develop the Materials or the Licensed Products for commercial use or commercial research.
This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and...Public Health Service • March 26th, 2019
This is the ____ amendment (“_____ Amendment”) of the agreement by and between the IC and Licensee having an effective date of ____ and having IC Reference Number L-XXX-200X/X (“Agreement”). This ___ Amendment, having IC Reference Number L‑XXX‑200X/X includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Shipping Information) and 3) Attachment 2 (Royalty Payment Information).
